Nutriband Celebrates New Trademark Registration for Key Technology
Nutriband Secures Trademark Registration for Key Innovations
Nutriband Inc. (NASDAQ: NTRB), a pioneer in the development of transdermal pharmaceutical products, has achieved a major milestone by receiving a Certificate of Registration from the United States Patent and Trademark Office. This certificate pertains to the mark "Nutriband™," a significant branding element for their innovative pharmaceutical technologies.
Significance of the Trademark Registration
The trademark registration is pivotal for Nutriband as it covers essential services such as product research and development, scientific research, and pharmaceutical research within the category of goods. This acknowledgment enhances the company's ability to protect its intellectual property and fortify its standing in the competitive pharmaceutical market.
Boosting Innovation with AVERSA Technology
At the heart of Nutriband's operations lies the AVERSA technology. This technology provides a unique approach to transdermal patches by adding aversive agents designed to curb potential drug misuse. By making the experience of misuse unpleasant, AVERSA technology ensures that critical medications remain accessible to patients while significantly enhancing safety protocols. Nutriband's leading product, AVERSA™ Fentanyl, exemplifies this commitment to patient safety and responsible medication management.
Partnerships and Progress
Nutriband is collaborating with Kindeva Drug Delivery on the commercial manufacturing scale-up for AVERSA™ Fentanyl. This product is poised to be the first under the AVERSA platform that will seek FDA approval. These steps mark a major leap towards bringing this technology to the market, addressing the urgent need for effective control over fentanyl use while preventing abuses.
Market Potential and Future Outlook
A recent market analysis suggests that AVERSA™ Fentanyl holds the potential for substantial annual U.S. sales, estimated between $80 million and $200 million. This projection underlines the impactful role that the AVERSA technology could play in the rapidly growing market for abuse-deterrent pharmaceuticals.
Nutriband's Vision for Safer Pharmaceuticals
As Nutriband refines its AVERSA technology, its vision extends beyond merely entering the market. The goal is to revolutionize how transdermal patches function, reducing the likelihood of drug misuse while still providing essential therapies to patients. With numerous patents granted in the U.S. and various other countries, Nutriband is positioned to lead innovation in this vital segment of healthcare.
About Nutriband Inc.
Nutriband Inc. primarily focuses on developing an extensive portfolio of transdermal pharmaceutical products. Its flagship initiative, the abuse-deterrent fentanyl patch utilizing AVERSA technology, represents a critical advancement in pharmaceutical safety. The technology is adaptable, allowing integration into a variety of transdermal systems aimed at countering drug diversion and misuse.
Contacting Nutriband
For more inquiries or detailed information, you can reach out to Nutriband Inc. directly. The company is committed to transparency and communication with its stakeholders.
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
Frequently Asked Questions
What is Nutriband known for?
Nutriband is primarily recognized for developing innovative transdermal pharmaceutical products, notably its AVERSA technology.
How does the AVERSA technology work?
AVERSA technology incorporates aversive agents into transdermal patches, discouraging potential drug abuse by making it an unpleasant experience.
What are Nutriband's future plans?
The company aims to complete the commercial manufacturing process for AVERSA™ Fentanyl and seek FDA approval to market this and other similar products.
What is the market potential for AVERSA Fentanyl?
Market analysis indicates that AVERSA™ Fentanyl could achieve peak annual sales ranging between $80 million and $200 million in the U.S. market.
How can I contact Nutriband for more information?
You can contact Nutriband directly via their phone number at 407-377-6695 or through email at info@nutriband.com.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.